scholarly journals MiR-10a in Pancreatic Juice as a Biomarker for Invasive Intraductal Papillary Mucinous Neoplasm by miRNA Sequencing

2021 ◽  
Vol 22 (6) ◽  
pp. 3221
Author(s):  
Natsuhiko Kuratomi ◽  
Shinichi Takano ◽  
Mitsuharu Fukasawa ◽  
Shinya Maekawa ◽  
Makoto Kadokura ◽  
...  
Keyword(s):  
Pancreatic Juice ◽  
Intraductal Papillary Mucinous Neoplasm ◽  
Invasive Carcinoma ◽  
Sequence Data ◽  
Mirna Sequence ◽  
Tissue Analysis ◽  
Mucinous Neoplasm ◽  
Paired Samples ◽  
Mirna Sequencing ◽  
Invasive Ipmn

New biomarkers are needed to further stratify the risk of malignancy in intraductal papillary mucinous neoplasm (IPMN). Although microRNAs (miRNAs) are expected to be stable biomarkers, they can vary owing to a lack of definite internal controls. To identify universal biomarkers for invasive IPMN, we performed miRNA sequencing using tumor-normal paired samples. A total of 19 resected tissues and 13 pancreatic juice samples from 32 IPMN patients were analyzed for miRNA expression by next-generation sequencing with a two-step normalization of miRNA sequence data. The miRNAs involved in IPMN associated with invasive carcinoma were identified from this tissue analysis and further verified with the pancreatic juice samples. From the tumor-normal paired tissue analysis of the expression levels of 2792 miRNAs, 20 upregulated and 17 downregulated miRNAs were identified. In IPMN associated with invasive carcinoma (INV), miR-10a-5p and miR-221-3p were upregulated and miR-148a-3p was downregulated when compared with noninvasive IPMN. When these findings were further validated with pancreatic juice samples, miR-10a-5p was found to be elevated in INV (p = 0.002). Therefore, three differentially expressed miRNAs were identified in tissues with INV, and the expression of miR-10a-5p was also elevated in pancreatic juice samples with INV. MiR-10a-5p is a promising additional biomarker for invasive IPMN.

Suggestion of new nomogram including inflammatory marker for predicting invasive carcinoma in intraductal papillary mucinous neoplasm of the pancreas.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 204-204
Author(s):  
In Woong Han
Keyword(s):  
Risk Factors ◽  
Factor Analysis ◽  
Risk Factor ◽  
Intraductal Papillary Mucinous Neoplasm ◽  
Inflammatory Markers ◽  
Invasive Carcinoma ◽  
Main Duct ◽  
Solid Portion ◽  
Mucinous Neoplasm ◽  
Invasive Ipmn

204 Background: Previous studies have analyzed that inflammatory markers, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI), associated with the presence of invasive carcinoma in patients with intraductal papillary mucinous neoplasm (IPMN). This study aimed to evaluate the correlation between the inflammatory markers and the invasive carcinoma in IPMN and propose a nomogram including inflammatory markers for predicting invasive IPMN. Methods: From 1995 to 2016, total 468 patients who underwent surgical resection at four institutions for histologically confirmed IPMN and the data were reviewed retrospectively. The patients with history of pancreatitis, other malignancies and without CA19-9 data or lymphocyte counts were excluded, the study cohort consisted of 365 patients. Variables with P < 0.05 in risk factor analysis were included in the nomogram. Results: Of 365 patients, 98 (26.8%) patients had invasive IPMN. In univariate analysis, high body mass index (BMI) ( P = 0.037), pre-operative bilirubin level ( P = 0.001), CA19-9 ( P < 0.001), NLR ( P = 0.019), PLR ( P = 0.002), ALI ( P = 0.001), main duct type (P < 0.001), the presence of solid portion ( P < 0.001) and tumor size (P = 0.086) were identified as risk factors for invasive IPMN. In multivariate analysis, pre-operative bilirubin level (P = 0.003), CA19-9 (P = 0.002), main duct type (P = 0.034) and the presence of solid portion (P < 0.001) were independent predictive markers for invasive IPMN. The nomogram was developed including all factors of risk factor analysis. Conclusions: The inflammatory markers were the risk factors for the presence of IPMN-associated invasive carcinoma. This nomogram may be useful in identifying patients with IPMN at risk of malignancy and for selecting which patients should undergo surgery. Further validation studies are needed to assess the predictive ability of nomogram including inflammatory markers.

Disease Spectrum of Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma

Pancreas ◽  
2013 ◽  
Vol 42 (8) ◽  
pp. 1267-1274 ◽  
Author(s):  
Mee Joo Kang ◽  
Kyoung Bun Lee ◽  
Jin-Young Jang ◽  
Wooil Kwon ◽  
Jae Woo Park ◽  
...  
Keyword(s):  
Intraductal Papillary Mucinous Neoplasm ◽  
Invasive Carcinoma ◽  
Mucinous Neoplasm ◽  
Disease Spectrum

Cytology from endoscopic retrograde cholangiopancreatography in the evaluation of invasive pancreatic head intraductal papillary mucinous neoplasm: A necessity?

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 266-266
Author(s):  
Alexandra M Roch ◽  
Michael Garrett House ◽  
Neil R Sharma ◽  
Jessica L Cioffi ◽  
John M DeWitt ◽  
...  
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Cancer Detection ◽  
Intraductal Papillary Mucinous Neoplasm ◽  
Pancreatic Head ◽  
Needle Aspiration ◽  
Endoscopic Retrograde ◽  
Biliary Endoprosthesis ◽  
Mucinous Neoplasm ◽  
Invasive Ipmn ◽  
Fluid Sampling

266 Background: Endoscopic retrograde cholangiopancreatography (ERCP) with brushing/fluid sampling has historically been the standard to establish invasive transformation of pancreatic head intraductal papillary mucinous neoplasm (IPMN). More recently, endoscopic ultrasound (EUS) with fine needle aspiration (FNA) has been employed for this purpose. We hypothesized that for patients with invasive IPMN, in the era of EUS FNA, there is no additional benefit of ERCP brushing/fluid sampling. Methods: A retrospective review of a prospectively maintained database of patients who underwent surgical resection for IPMN at a single academic center (1992-2014) was performed. Patients with invasive pancreatic head IPMN on surgical pathology were included. Cytopathology was considered positive if it showed adenocarcinoma or markedly atypical cells. Results: Of the 74 patients with invasive IPMN, 55 had a pancreatic head neoplasm. Preoperatively, 4 patients had neither EUS nor ERCP, 27 had only 1 endoscopic study (ERCP n=16, EUS n=11), and 24 had both EUS and ERCP. In 11 patients with EUS, 8 had positive FNA (73% sensitivity for cancer detection). In 16 patients with ERCP (brushing n=7, fluid n=9), 5 had positive cytology resulting in 31% sensitivity. Further analysis revealed 29% and 33% sensitivity for brushing and fluid sampling, respectively. When both procedures were performed (n=24; EUS+ERCP fluid n=10, EUS+ERCP brushing n=14), the sensitivity was 75%, but ERCP cytology changed the diagnosis in only 2 patients. EUS FNA was performed regardless of ERCP cytology results in 18 patients (after brushing n=6, after fluid sampling n=4, same day n=8; median interval=4 days). 6 patients had negative cytology from both EUS and ERCP. Conclusions: In patients with invasive pancreatic head IPMN, sensitivity of ERCP cytology for cancer detection was poor (31%), making an impact on diagnosis in only 2/55 patients. EUS FNA was performed in 75% patients regardless of ERCP cytology results. Aside from the therapeutic impact of ERCP (biliary endoprosthesis in jaundiced patients), its cytological role is limited, resulting in unnecessary and potentially avoidable cost.

scholarly journals The efficacy of pancreatic juice cytology with liquid-based cytology for evaluating malignancy in patients with intraductal papillary mucinous neoplasm

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Kazuya Miyamoto ◽  
Kazuyuki Matsumoto ◽  
Hironari Kato ◽  
Ryuichi Yoshida ◽  
Yuzo Umeda ◽  
...  
Keyword(s):  
Pancreatic Juice ◽  
Intraductal Papillary Mucinous Neoplasm ◽  
Low Grade ◽  
Cell Recovery ◽  
International Consensus ◽  
Mucinous Neoplasm ◽  
Liquid Based Cytology ◽  
Pancreatic Juice Cytology ◽  
Almost All ◽  
Malignant Ipmn

Abstract Background Pancreatic juice cytology (PJC) is a tool for diagnosing malignant intraductal papillary mucinous neoplasm (IPMN); however, the accuracy is insufficient using the conventional method. Liquid-based cytology (LBC) improves the cell recovery rate, and almost all cells can be evaluated. We evaluated the efficacy of PJC with LBC for malignant IPMN. Methods We retrospectively analyzed 90 patients with suspected malignant IPMN who underwent PJC before pancreatectomy. PJC with smear and LBC methods was conducted in 52 patients (between June 2003 to December 2011) and 38 patients (between January 2012 to December 2018). Based on the imaging studies, all of the patients were classified according to the international consensus guidelines for IPMN revised in 2017. Results Of the 90 patients, 43 (48%) had malignant IPMN (high-grade dysplasia or invasive carcinoma), and the remaining patients had non-malignant IPMN (intermediate- or low-grade dysplasia). LBC increased the accuracy of PJC for the diagnosis of malignant IPMN (smear method: 56% [29/52] vs. LBC method: 76% [29/38]; P = 0.044). In a multivariate analysis, LBC was a significant factor influencing the accurate diagnosis of PJC (odds ratio: 3.52; P = 0.021). Furthermore, LBC increased the accuracy of PJC for malignant IPMN in patients with worrisome features (smear method: 66% [19/29] vs. LBC method: 93% [14/15]; P = 0.043). Conclusions LBC increases the accuracy of PJC for diagnosing malignant IPMN compared with the conventional smear method.

Tu2013 - Human Organoid Models of Intraductal Papillary Mucinous Neoplasm (IPMN) Derived from Pancreatic Juice

2018 ◽  
Vol 154 (6) ◽  
pp. S-1369
Author(s):  
Emiri Kita ◽  
Kentaro Sudo ◽  
Taro Hara ◽  
Yoshiaki Maru ◽  
Taketo Yamaguchi ◽  
...  
Keyword(s):  
Pancreatic Juice ◽  
Intraductal Papillary Mucinous Neoplasm ◽  
Mucinous Neoplasm

scholarly journals Intraductal Papillary Mucinous Neoplasm of the Pancreas: An Update

Scientifica ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-20 ◽  
Author(s):  
Shu-Yuan Xiao
Keyword(s):  
Intraductal Papillary Mucinous Neoplasm ◽  
Invasive Carcinoma ◽  
Ductal Adenocarcinoma ◽  
Cystic Tumor ◽  
Main Duct ◽  
Branch Duct ◽  
Mucinous Neoplasm ◽  
Invasive Component ◽  
Small Branch ◽  
Asymptomatic Patients

Intraductal papillary mucinous neoplasm (IPMN) is a cystic tumor of the pancreas. The etiology is unknown, but increasing evidence suggests the involvement of several tumorigenesis pathways, including an association with hereditary syndromes. IPMN occurs more commonly in men, with the mean age at diagnosis between 64 and 67 years old. At the time of diagnosis, it may be benign, with or without dysplasia, or frankly malignant with an invasive carcinoma. Tumors arising from the main pancreatic duct are termed main-duct IPMNs, those involving the branch ducts, branch-duct IPMNs. In general, small branch-duct IPMNs are benign, particularly in asymptomatic patients, and can be safely followed. In contrast, main-duct tumors should be surgically resected and examined carefully for an invasive component. In the absence of invasion, patient’s survival is excellent, from 94 to 100%. For patients with an IPMN-associated invasive carcinoma, the prognosis overall is better than those with ade novopancreatic ductal adenocarcinoma, with a 5-year survival of 40% to 60% in some series. However, no survival advantage can be demonstrated if the invasive component in an IPMN patient is that of the conventional tubular type (versus mucinous carcinoma). Several histomorphologic variants are recognized, although the clinical significance of this “subtyping” is not well defined.

Morules in Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas

Pancreas ◽  
2012 ◽  
Vol 41 (4) ◽  
pp. 651-652 ◽  
Author(s):  
Yoko Tateno ◽  
Minoru Esaki ◽  
Kazuaki Shimada ◽  
Hidenori Ojima ◽  
Yae Kanai ◽  
...  
Keyword(s):  
Intraductal Papillary Mucinous Neoplasm ◽  
Invasive Carcinoma ◽  
Carcinoma Of The Pancreas ◽  
Mucinous Neoplasm
Sign in / Sign up

Export Citation Format

Share Document